<DOC>
	<DOCNO>NCT00081055</DOCNO>
	<brief_summary>RATIONALE : OTI-010 may effective graft-versus-host disease prophylaxis ( prevention ) patient undergo donor peripheral stem cell transplantation hematologic malignancy ( cancer blood bone marrow ) . PURPOSE : This randomized phase II trial study well OTI-010 work prevent graft-versus-host disease patient undergo donor peripheral stem cell transplantation hematologic cancer .</brief_summary>
	<brief_title>OTI-010 Graft-Versus-Host Disease Prophylaxis Treating Patients Who Are Undergoing Donor Peripheral Stem Cell Transplantation Hematologic Malignancies</brief_title>
	<detailed_description>OBJECTIVES : - Compare safety efficacy OTI-010 v placebo graft-versus-host disease prophylaxis patient hematologic malignancy undergo HLA-identical sibling match peripheral blood stem cell transplantation . OUTLINE : This randomize , double-blind , placebo-controlled , multicenter study . Patients stratify accord age ( 18 34 v 35 55 ) donor/recipient gender ( female donor/male recipient v female donor/female recipient v male donor/female recipient v male donor/male recipient ) . - Conditioning regimen : Patients receive cyclophosphamide IV daily day -5 -4 undergo total body irradiation twice daily day -3 -1 OR busulfan IV 2 hour every 6 hour day -7 -4 cyclophosphamide IV daily day -3 -2 . - Graft-versus-host disease prophylaxis : Patients receive methotrexate IV day 1 , 3 , 6 , 11 . Patients also receive cyclosporine orally IV ( 1-4 hour ) twice daily begin day -1 continue least 6 month follow taper 1 year transplantation . - OTI-010 therapy : Patients randomize 1 3 treatment arm . - Arm I : Patients receive placebo IV 4 hour peripheral blood stem cell transplantation ( PBSCT ) day 0 . - Arm II : Patients receive OTI-010 IV 4 hour PBSCT day 0 . - Arm III : Patients receive high dose OTI-010 IV 4 hour PBSCT day 0 . - Allogeneic stem cell transplantation : Patients undergo allogeneic PBSCT day 0 . Patients follow 18 week , 6 , 9 , 12 month , every 6 month 1 year , annually 3 year . PROJECTED ACCRUAL : A total 99 patient ( 33 per treatment arm ) accrue study within 5 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Busulfan</mesh_term>
	<mesh_term>Cyclosporins</mesh_term>
	<mesh_term>Cyclosporine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm diagnosis 1 follow hematologic malignancy : Acute lymphoblastic leukemia , meet 1 follow criterion : In first second remission In early first second relapse* Acute myeloid leukemia , meet 1 follow criterion : In first second remission In early first second relapse* Chronic myelogenous leukemia Chronic accelerate phase Any follow myelodysplastic syndrome : Refractory anemia ( RA ) RA ring sideroblast RA excess blast NOTE : * &lt; 24 % marrow blast &lt; 5 % peripheral blood blast ( within 10 day begin condition regimen ) No secondary acute leukemia Prior CNS tumor involvement allow provided patient asymptomatic evidence CNS disease lumbar puncture CT scan brain Must 6/6 HLAidentical sibling donor available PATIENT CHARACTERISTICS : Age 18 55 Performance status Karnofsky 70100 % Life expectancy Not specify Hematopoietic Not specify Hepatic Bilirubin &lt; 2 time upper limit normal ( ULN ) SGOT &lt; 10 time ULN Hepatitis B core antigen , surface antigen , eantigen negative Hepatitis B DNA negative Hepatitis C RNA negative Renal Creatinine clearance ≥ 60 mL/min Cardiovascular LVEF ≥ 50 % MUGA echocardiogram No right side heart failure Pulmonary FEV_1 &gt; 50 % predict DLCO ≥ 50 % predict ( correct anemia ) Oxygen saturation ≥ 97 % room air No pulmonary hypertension Immunologic HIV1 2 antibody negative HIV1 antigen negative HTLVI II antibody negative No active infection Other CNS function normal No uncontrolled alcohol substance abuse within past 6 month No concurrent underlie medical condition would preclude study participation Not pregnant Negative pregnancy test Fertile patient must use 2 effective method contraception PRIOR CONCURRENT THERAPY : Biologic therapy No prior allogeneic autologous hematopoietic stem cell transplantation No concurrent medication accelerate neutrophil platelet engraftment except filgrastim ( GCSF ) Chemotherapy Not specify Endocrine therapy Not specify Radiotherapy Not specify Surgery No prior solid organ transplantation Other More 30 day since prior investigational agent device No concurrent investigational agent device No concurrent antiinfective therapy except prophylactic therapy No concurrent condition regimen agents No concurrent herbal remedy except multivitamin No concurrent graftversushost disease prophylaxis medication ( e.g. , ursodeoxycholic acid )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>December 2014</verification_date>
	<keyword>graft versus host disease</keyword>
	<keyword>adult acute lymphoblastic leukemia remission</keyword>
	<keyword>recurrent adult acute lymphoblastic leukemia</keyword>
	<keyword>adult acute myeloid leukemia remission</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>accelerated phase chronic myelogenous leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>refractory anemia</keyword>
	<keyword>refractory anemia excess blast</keyword>
	<keyword>refractory anemia ring sideroblast</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
</DOC>